F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00721799|
Recruitment Status : Completed
First Posted : July 24, 2008
Results First Posted : October 3, 2017
Last Update Posted : August 6, 2019
University of Iowa
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Yusuf Menda, University of Iowa
|Study Design||Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Diagnostic|
Head and Neck Neoplasms
Drug: 18F-Fluorothymidine PET scan
- HPV (human papilloma virus) status of tumors not available.
- Therapy heterogeneity in the therapy; radiotherapy fairly consistent but chemotherapy regimens varied.
- Small sample size is limiting.